Mobile game software company Mobile Digital Media gets $2M recapitalization
Mobile Digital Media, a company that builds software that runs games and other applications on mobile devices, has raised $2 million from Cross Atlantic Partners and Sofinnova Partners, according to VentureWire.
The company’s web site features some of its marquee products — rather old-school games like… Continue Reading
Life-science briefing: Wednesday, March 19, 2008
TODAY’S HEADLINES:
Paris-based Stentys takes $18M for “bifurcated” stents (release)
Blood analyzer IntelliDx raises $22M (PDF release)
Cancer-test biotech Calderome changes name to VeraCyte (VentureWire)
Predictive Biosciences names Peter Klemm as CEO (release)
Paris-based Stentys takes $18M for “bifurcated” stents – Stentys, a Paris-based medical device maker, raised $18 million in… Continue Reading
Life sciences briefing: Thursday, Jan. 24, 2008
TODAY’S HEADLINES:
Satoris gets $5M for Alzheimer’s test (VentureWire)
Endotis Pharma pulls in €25M for clot-busting and cancer drugs (release)
Germany’s Direvo Biotech strikes drug-development pact with MedImmune (release)
OrthoAccel gets $1.3M for device to speed orthodonture (VW)
Medical-management software co. Accuro Healthcare files for $144M IPO (Edgar)
Psilos Group raises… Continue Reading
Life sciences briefing: Thursday, Dec. 13, 2007
TODAY’S HEADLINES:
Fovea Pharma sees €30M for eye drugs (release)
Ascendis Pharma raises €18M for time-release drugs (PDF release)
Arcion draws $9M for topical pain drugs (VentureWire, sub req’d)
Saladax Biomedical raises $8M for chemotherapy diagnostics (VW)
MedAssets prices IPO at top of range, raises up to $221M (IPO Home)
Pequot… Continue Reading
GlycoVaxyn pulls in $9.3M for conjugated vaccines
Zurich’s GlycoVaxyn, a biotech developing new “conjugated vaccines”, raised a $9.3 million first funding round. Sofinnova Partners and Index Ventures supplied the investment.
The company will use the funding to push forward with the development of vaccines for bacterial infections, and plans to begin clinical trials… Continue Reading
Noxxon Pharma draws $50M for aptamer drugs
Noxxon Pharma, a Berlin-based biotech, raised 37 million euros ($50 million) to help push its first aptamer-based drug candidates for kidney and eye disease into clinical trials.
The main new investors included TVM Capital, Sofinnova Partners, and Edmond de Rothschild Investment Partners.
Aptamers are short stretches of… Continue Reading